Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries.[2] Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.

Twist Bioscience
Industrysynthetic biology
Founded2013; 10 years ago (2013)
ProductsGenes and gene fragments, NGS products
RevenueIncrease $54.2 million(2019)[1]
Number of employees

The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.[3]

In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes.[4]

References edit

  1. ^ "Twist Bioscience | Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results".
  2. ^ Strickland, Eliza (December 23, 2015). "DNA Manufacturing Enters the Age of Mass Production". IEEE Spectrum: Technology, Engineering, and Science News.
  3. ^ Yassif, Jaime; O'Prey, Kevin; Isaac, Christopher (November 2021). "Strengthening Global Systems to Prevent and Respond to High-Consequence Biological Threats" (PDF). Nuclear Threat Initiative. Archived (PDF) from the original on 2022-07-09. Retrieved 2022-07-09.
  4. ^ "CAD Platform Developed by GP-Write and Twist to Launch Large Genome Projects". Genetic Engineering & Technology News. May 12, 2021.